since the Department of Health stopped publishing its national audits of the 1980s and 1990s. Electroconvulsive therapy is still used, on several hundred thousand people internationally every year (Leiknes, Jarosh-von Schweder, & Hoie, 2012; Read, Bentall, Johnstone, Fosse, & Bracken, 2013) . A review, of 70 studies, found 'large variation between continent, countries and regions in utilization, rates and clinical practice' (Leiknes et al., 2012, p. 296) . High users include Australia, Belgium, Norway, Sweden, and the United States. Financial arrangements also vary. In the United Kingdom, the vast majority of ECT is administered within the publicly funded National Health Service (Buley, Copland, & Hodge, 2017) , whereas in other countries, including the United States and Australia, for example, private psychiatrists play a leading role.
ECT remains one of the most controversial of psychiatric treatments. Several metaanalyses conclude it is an effective treatment for depression (Gabor & Lazlo, 2005; Greenhalgh, Knight, Hind, Beverley, & Walters, 2005; Kho, van Vreewijk, Simpson, & Zwinderman, 2003; Pagnin, de Queiroz, Pini, & Cassano, 2004; UK ECT Review Group, 2003; Van der Wurff, Stek, Hooogendijk, & Beekman, 2003) . A 2010 review, however, noted that none of these meta-analyses identified any evidence that ECT had any benefit, compared to placebo, beyond the end of treatment and that there is no evidence that ECT prevents suicide (Read & Bentall, 2010) . The most recent review also failed to find a single study showing that ECT is superior to placebo beyond the end of treatment (Read & Arnold, 2017) . The National Institute of Care and Excellence (N.I.C.E., 2009) has stated that 'Further research is urgently required to examine the long-term efficacy and safety of ECT'. Other reviews (Rasmussen, 2009; Ross, 2006) had reached similar conclusions to the 2010 review, such as 'Rigorously defined endogenously depressed patients did exceptionally well with sham ECT, as well as with real ECT' (Rasmussen, p. 59) . The controversy also focuses on the extent to which ECT causes long-lasting memory dysfunction and increases mortality (Breggin, 2008; Rose, Fleischmann, Wykes, Leese, & Bindman, 2003; Rose, Fleischman, & Wykes, 2004; Sackeim et al., 2007) .
The controversy includes the issues of when ECT should be used, and on whom. Some consider it the treatment of choice for several disorders. Others argue it should never be used. A common position is that it should be used only as a last resort, and only when other treatments have failed. The UK government guidelines (N.I.C. E., 2009, 2017) promote this position. N.I.C.E. guidelines (2017) currently state:
Consider ECT for acute treatment of severe depression that is life-threatening and when a rapid response is required, or when other treatments have failed.
Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment. This is repeated, almost verbatim by the UK's Royal College of Psychiatry (2017) . Controversy is also to be found about why ECT has consistently been targeted at women and older people, internationally, and whether the frequent use of compulsion is ethical or evidence-based (Breggin, 2008; . In England, the Mental Health Act 2007 revised the legislation relating to treatment without consent (s58A), introducing additional safeguards, and guidelines to second opinion appointed doctors (SOADs; Department of Health, Ministry of Justice, 2009). These safeguards include the requirement that when detained patients are deemed incapable of giving consent the SOAD must testify that it is appropriate for the patient to receive ECT. Prior to this, the SOAD must consult two other persons, one of which must be 'a nurse concerned with the patient's medical treatment' and the second 'another person professionally concerned with the patient's medical treatment who is neither a nurse nor a doctor'. National Institute of Clinical Excellence (2017) guidelines also state:
Clinical status should be assessed following each ECT session and treatment should be stopped when a response has been achieved, or sooner if there is evidence of adverse effects.
This study, therefore, aimed to assess the following: (1). whether N.I.C.E. guidelines about psychological treatments being tried before ECT, and about monitoring negative and positive outcomes, are being followed. (2). whether usage is increasing, decreasing, or remaining steady. (3). whether the treatment continues to be disproportionately used on women and old people. (4). how much compulsion is being used, and whether legislation regarding SOADs is being complied with.
Method
These research questions were addressed using a cross-sectional, retrospective design targeted at all publicly funded ECT providers in England, addressing ECT usage during 2011 ECT usage during , 2013 ECT usage during , and 2015 . These years were selected so as to assess both recent practice and recent change over time, while maximizing the probability of the Trusts being able to provide data. Ethical approval was not required as there was no interaction with patients.
Data gathering
In November 2016, a Freedom of Information (FOI) Act request was sent to the FOI Officer of all 60 publicly funded providers of mental health services in England, including 56 National Health Service (NHS) Trusts. The Act entitles anyone to request information from any public sector body. Our request consisted of the following questions, developed specifically for this study to address our research questions:
(1). For each of the years 2011, 2013 and 2015, how many patients received ECT (Please break down the three answers in this section for males/females) a. How many of these were under 18? b. How many of these were over 60? 
Participants
None of the four non-NHS providers provided data, with three explaining they were not obliged to do so because they were 'not a public authority' and one failing to respond at all. Thirty-two of the 56 NHS Trusts (57.1%) provided some usable data. The number replying to specific questions ranged from 32 (2015 ECT totals) to four (outcome data).
Data analysis
Being essentially an audit, most of the data are presented in descriptive format. The exceptions were the use of two-tailed t-tests to determine whether the means of the annual totals differ, and Spearman's rank correlation coefficients to assess the stability of differential usage of ECT by the various Trusts over time.
Results

Psychological therapy
Only 10 Trusts answered 'How many people had ECT without receiving a N.I.C.E. recommended psychological therapy in 2015?' Seven offered no explanation for not answering. The other 15 used one or more of the following explanations: 'not recorded' (7); recorded but not collated -so not easily accessible (5); beyond the amount of information that can reasonably be expected to be provided without charging a fee (Section 12 of the FOI Act) (6). The 10 Trusts reported that 210 of 767 people (27.4%) received ECT without first receiving psychological therapy (see Table 1 ). The range was from 100% in two Trusts The average number of ECT recipients per Trust for the 3 years (n = 29) were as follows: 2011 -48.72; 2013 -54.37; 2015 -47.76 . None of the differences between the three pairs of means were significantly different. The pattern of differences between Trusts remained stable over time. Spearman's rank correlation coefficients between the three pairs of years were as follows: 2011-2013 = 0.90; 2013-2015 = 0.89; 2011-2015 = 0.87 ; these were all significant at the p < .0001 level.
Gender and age Twenty-eight Trusts provided gender data, for 3,901 people. Of these, 2,579 (66.1%) were women. The range was from 48.8% (West London) to 85.7% (South Staffordshire & Shropshire) . In 25 of the 28 Trusts (89%), more than 55% were women. In fifteen (54%), women were at least twice as likely to receive ECT as men (≤66.7%). Women in Oxford were three times more likely than men to receive ECT (75.1%); and six times more likely in South Staffordshire & Shropshire.
Twenty-nine Trusts answered the age-related questions. Of 3,925 ECT recipients, 2,216 (56.5%) were over 60. Table 1 shows that the lowest rates were in Camden (22.2%) and Greater Manchester (31.0%), and the highest in South Staffordshire & Shropshire (82.1%), Barnet, Enfield & Haringey (75.5%) and Birmingham & Solihull (73.5%) . In 21 of 29 Trusts (72%), at least half of ECT recipients were aged over 60.
Only 0.2% of ECT recipients were children, that is, aged under 18. Only five Trusts had used ECT on children in any of the 3 years. The highest rate across the 3 years was in Birmingham & Solihull (2.6%, 4 out of 155).
Diagnoses
Data on 2,564 people, from 22 Trusts, showed that most people were diagnosed with Depression (2,186; 85.3%). The range was from 35.0% (Black Country) and 40.5% (South Staffordshire & Shropshire) to 100% for three Trusts (Coventry & Warwickshire, Dorset, and West London). Other diagnostic groupings were as follows: psychosis (135, 5.3%); bipolar/mania (51, 2.0%); personality disorder (39, 1.5%), anxiety (18, 0.7%), and dementia (3, 0.1%). Twelve of the 22 Trusts (54%) administered ECT to at least one person with a primary diagnosis for which ECT is not indicated (Anxiety -7 Trusts; personality disorder -6; dementia -1). In South Staffordshire & Shropshire, 23 of 84 ECT recipients (27.4%) were diagnosed with personality disorder.
Consent
Data on 2,987 people, from 22 Trusts, indicated that 1,157 (38.7%) had been given ECT without their consent. Table 1 shows that this ranged from 15.3% (Surrey & Borders) to 72.2% (Hertfordshire) and 100% (Black Country).
Professions used by SOADs, to certify ECT in the case of people deemed to lack capacity to give consent, were as follows: occupational therapists (80%); nurses (65%); physiotherapists (45%); clinical psychologists (30%); pharmacists (30%); doctors (15%); social workers (15%); dieticians (5%); and ward managers (5%). Fourteen of the 20 Trusts that provided these data (70%) were using the combination of professionals required by the Mental Health Act.
Efficacy
Methods
Nine Trusts (28%) provided no information about the measures they used in relation to clinical outcomes. The most commonly used, by 16 of the 23 (70%) that did provide information, was the Clinical Global Impressions (CGI) scale, in which a single clinician subjectively assesses severity of psychopathology, and change from start of treatment, on 7-point scales. Table 1 shows that 13 of the 23 Trusts (56.5%) used one or more of the following validated scales (see Table 1 ): Mini-Mental State Examination [MMSE] (5 Trusts); Montgomery-Asberg Depression Rating Scale (4); Hamilton Depression Rating Scale (3); Hospital Anxiety and Depression Scale (1); Health of the Nation Scale (1); and Beck Depression Inventory (1). Six used only the subjective CGI scale. The other four described a range of other subjective approaches to assessing efficacy, such as 'ward observations' and 'psychiatrist review'.
Measures and assessments were administered regularly during treatment, but no Trusts mentioned any follow-up assessments after the end of treatment. None referred to any independent assessments, at any time by anyone not involved in delivering ECT.
Data
Only four of the 33 Trusts (12.1%) provided any actual data about clinical outcomes. Two provided some data from the 7-pointCGI scale. Cornwall reported findings for after each individual administration of ECT rather than for each patient. Their findings were: significantly improved -21 (6.8%); much improved -96 (31.0%); minimally improved -96 (31.0%); no change -81(26.1%); minimally worse -7 (2.3%); much worse -2 (0.6%); significantly worse -1 (0.3); and six not assessed. Coventry & Warwickshire, reporting on people rather than individual treatments, wrote: '100% CGI 6 or 7 prior to treatment (severely ill/amongst the most severely ill). 95% CGI 1, 2, or 3 post-course (very much improved, much improved, improved). 5% 4 no change'.
Coventry & Warwickshire also reported that 'All Hospital Anxiety and Depression Scale scores improved at end of course to varying degrees'. Greater Manchester West, who had used the CGI and the Montgomery-Asberg Depression Rating Scale, simply reported that 'all patients reported improvement with ECT'. Surrey & Borders, who had provided no information about how efficacy had been measured, stated '80-90% improvement'. No follow-up data, beyond the end of treatment, were reported by any Trusts. . The other seven Trusts offered more general comments such as 'short term memory is monitored along with physical health assessment'. Measures and assessments were administered regularly during treatment.
Adverse effects
Four Trusts mentioned assessment beyond the end of treatment. Only three Trusts included information about who did the assessing: 'Patient's own views and their treating clinician's assessment', 'Consultant reviews' and 'Subjective questions, gathering the opinions of staff, carers, relatives'. None referred to any independent assessments by anyone not directly involved.
Data
Only four Trusts provided actual data on adverse effects. Coventry & Warwickshire reported that of their 54 ECT recipients '4.9% scored above 24 using MMSE post-treatment (normal range)', indicating that 95.1% had mild, moderate, or severe cognitive impairment following ECT. Greater Manchester West reported that of their 40 ECT patients, '6 short term memory loss (resolved after 2-3 days); seven patients had headaches post-ECT resolved with analgesics'.
Surrey and Borders reported that their 121 patients experienced only 'headaches' and 'nausea'. Leicestershire, with 47 ECT recipients, stated 'there were no adverse effects of ECT on any patient in 2015'. No Trusts reported any follow-up data on adverse effects beyond the end of treatment.
Discussion
Psychological therapy Unfortunately, the data gathered in the current study cannot reliably answer the question 'How many people had ECT without receiving a N.I.C.E recommended psychological therapy?' because only 10 of 32 (31%) responded to this question. This represents just 18% of the 56 Trusts that were asked the question. Failure to record or collate this information suggests that most Trusts are not interested in, or aware of, N.I.C.E guidelines on this matter. The fact that in at least two Trusts ECT was given to everyone (158 in total) without any of them having first received psychological therapy is a flagrant breach of N.I.C.E guidelines. It seems some clinicians and managers remain unconvinced of the need for an integrated, evidence-based approach involving the non-medical treatments recommended by N.I.C.E. N.I.C.E. supports its recommendations for the use of psychological treatments for depression with a range of studies and reviews, including a meta-analysis that examined 17 randomized control trials involving over 3,000 participants and found an overall benefit of psychological therapies compared with usual care, particularly for CBT-type interventions (Van t'Hof, Cuijpers, Waheed, & Stein, 2011). Unlike ECT, psychological treatments can teach new techniques which last beyond the end of treatment and which may contribute to self-help and early recognition and intervention. Psychological treatments involve active involvement rather than the passive role of a 'patient' receiving a 'treatment' and, hopefully, a collaborative relationship of the kind clients might need to prevent or overcome further 'episodes'. Furthermore, E.C.T. cannot address the various well-documented psychosocial causes of depression such as loss, neglect and abuse (Cromby, Harper, & Reavey, 2013; Kendler, Hettema, Butera, Gardner, & Prescott, 2003) . One additional reason why there is so much evidence for the efficacy of psychosocial interventions and so little for E.C.T. relates to the implied messages about causation that accompany the treatments. Assumptions that one's difficulties are caused by their being something wrong with one's brain are associated not only with greater prejudice from other people, but with pessimism about recovery and less effort to improve one's own situation (Kvaale, Haslam, & Gottdiener, 2013; Read, Haslam, Sayce, & Davies, 2006) .
Numbers
A comprehensive survey by the Royal College of Psychiatrists (RCP) estimated that 27,000 people received ECT in Great Britain in 1980 and that usage had halved since the early 1970s (Pippard & Ellam, 1981) . Department of Health reports for England (1989 England ( , 1999 show that the number of individual administrations of ECT fell from 159,600 in 1980 to 109,707 in 1989, and then to 65,928 in 1999 . If the average number of administrations per course of treatment was six, this would mean that the number of people given ECT in England had fallen to about 18,000 in 1989, and 11,000 in 1999. Extrapolating from the last report by the Department of Health (2003), on the first quarter of 2002, produces an annual figure of 9,200 people.
An ECT Accreditation Service (ECTAS) survey estimated that the number of people receiving ECT in England in 2006 had continued to fall, substantially, to about 1,300 (Cresswell, Hood, & Lelliott, 2007) . A subsequent ECTAS report gathered responses from 78 of 104 ECT clinics in England and Wales, for 2012/2013 (Cresswell & Hodge, 2013) . It can be estimated that in the 104 clinics 2,305 people received ECT, or 2,527 if one includes those receiving more than two courses during the year. Given that there were 71 English clinics reporting, it can be further estimated that about 2,385 of these courses occurred in England.
The current study can also provide only an estimate. The current number of N.H.S. mental health Trusts is 56. Multiplying the average number of annual ECT recipients for 29 Trusts for the years 2011, 2013, and 2015 combined (50.40) by 56, produces a total of 2,822 people, with totals for each year as follows: 2011 -2,728; 2013 -3,045; 2015 -2,675 .
A 2017 article in the Guardian newspaper, headlined 'Electroconvulsive therapy on the rise again in England', reported on the responses of 44 of 56 English mental health Trusts to an FOI request (Davies & Duncan, 2017) . The article reported that in those 44 Trusts 'more than 2,200' people received ECT in 2015/2016 and that this was a rise from 2012 to 2013. The actual numbers for each of the four years covered were as follows: 2012 /13 -2070 /14 -2229 2014 /15 -2149 and 2015 /16 -2189 (P. Duncan, Guardian newspaper, personal communication, 2017 . These variations are smaller than those found in the current study, which produced an increase of 11.2% in ECT usage over 2 years followed by a decrease of 12.2% during the subsequent 2 years, with neither of those changes approaching significance. So the change over a 3-year period noted by the Guardian is actually part of the 'considerable fluctuation over the last 4 years' acknowledged in the same article.
Extrapolating from the 44 responding Trusts to all 56 Trusts produces estimates ranging from 2,635 to 2,837, and an average of 2,748 people per year for the period 2012/ 13 to 2015/16. This is similar to the 2,822 figure produced by the current study.
Combining the current study with the ECTAS reports for 2006 and 2012/2013 and the Guardian survey, it is reasonable to assume that the number of people in England receiving ECT annually within NHS Trusts had continued its steady decline until around 2006 (to a low of about 1,300), but then increased and stabilized for a few years at about double that number.
It remained between 2,300 and 3,100 from 2011 to 2015/16. The latest ECTAS report, for 2016/17, has just reported, however, a 'decline from previous years', to 2,135 (Buley et al., 2017) . The decline of 12.2% from 2013 to 2015 in the current survey, although not statistically significant by itself, is consistent with the ECTAS conclusion that, after a brief upturn, the 40-year decline in the use of ECT in England has recommenced but has not yet passed the 2006 low point of 1,300.
Variation
This large decline over several decades in England is matched by most other countries, but, as noted earlier, there is large variation between countries (Leiknes et al., 2012) .
Huge regional variation within countries has also been mentioned in most reports for several decades. The 1980 RCP survey found fivefold differences in usage between regions of Great Britain and 17-fold differences between hospitals. Variations are not reported by ECTAS. The current study, however, found a 12-fold difference per 100,000 between the highest and lowest Trusts. As the 1980 RCP report suggested, this is probably explained by the wide range of personal opinions about ECT held by individual psychiatrists.
Gender and age
The current study's finding that women are twice as likely to receive ECT is remarkably consistent, in most countries, for decades (Leiknes et al., 2012; . The 1981 RCP report found that 69% of ECT recipients were women. The 2003 Department of Health figure was 70%, and the latest ECTAS survey reported 66% (Buley et al., 2017) . These findings parallel the similar levels of disproportionate current prescribing of antidepressants and, before that, benzodiazepines, to women. The most recent ECTAS report found that the proportion is even higher for maintenance ECT -74%.
The disproportionate use of ECT on older people, found in the current study, is also consistent with many other findings, internationally, over many decades (Leiknes et al., 2012; . In the 2012/2013 ECTAS survey, for instance, the average age was 62 (Cresswell & Hodge, 2013) . In the latest ECTAS report 59% were 60 or over, and 35% were 70 or over (Buley et al., 2017) ; with even higher proportions for maintenance ECT: 68% 60 or over, 50% 70 or over. The mean age overall was 61, and the mean for maintenance ECT was 66.
If these findings about age and gender are partly or completely explained by higher levels of depression then one might wonder whether treatments that addressed the social causes of the gender's or age group's greater distress might be deployed rather than treatments that are blind to such causal disparities. Poverty and loneliness come to mind as possible candidates.
The largest prospective study of cognitive dysfunction caused by ECT (Sackeim et al., 2007) found that 12% met the criterion for 'marked and persistent retrograde amnesia', and that women and older people, the two groups who receive ECT disproportionately, had particularly high rates of memory loss. The researchers pointed out women have a lower seizure threshold and electrical dosage was often not adjusted accordingly. The finding that older people are particularly susceptible to the cognitive dysfunction caused by administering electric shocks to the brain was not new (Sackeim, 2004) and is consistent with findings that they are also particularly susceptible to many of the adverse effects of antidepressant drugs (Coupland et al., 2011) . This set of findings suggests that psychological therapies may be particularly appropriate for older people and that it is particularly essential that they are not offered E.C.T. before being offered psychological therapy.
Diagnosis
The vast majority of diagnoses were depression (85%), which is broadly consistent with the most recent ECTAS report (90%). The ECTAS report, however, identified none of the diagnoses for which ECT is not recommended that were identified in the current study (in just over half the Trusts). This may be because of bias created by ECTAS using forcedchoice responses 'based on NICE guidance' (Buley et al., 2017) . The use of ECT on people diagnosed with personality disorders, in six Trusts, is of concern. Consent A substantial minority, 38%, is still being given ECT against their will. As with previous studies, there is enormous variation, in this case from 0% to 100%. It appears the proportion given ECT without giving consent is rising (Buley et al., 2017) . The proportion, including 'emergencies ', was only 18% in 1999 and 20% in 2002 (Department of Health, 1999 . ECTAS reported that in 2012/13 35% were detained under the Mental Health Act and deemed incapable of giving consent; by 2016/2017, this figure had risen to 41%.
It is of concern that six of the 20 Trusts that provided relevant information appeared to be in breach of section 58A of the Mental Health Act in that they were not using the correct combination of professionals to provide second opinions. The ECTAS reports do not monitor this.
Efficacy
The most commonly used method for assessing efficacy was the CGI Scale. This very basic scale, which takes just a few seconds to complete, seems inadequate to properly assess an invasive and potentially dangerous intervention. Furthermore, there is no reason to believe that this inevitably subjective and simple approach to assessment was conducted by anyone other than the treating staff, who are necessarily potentially biased. There was no evidence, from any Trusts, of any attempt at independent assessments. There was also no evidence of any assessment of whether any gains perceived by the clinicians lasted beyond the end of treatment. The 13 Trusts that used validated scales are, however, to be commended.
That only four Trusts could provide any actual data, and that none could provide any follow-up data, is of serious concern. It suggests that most Trusts do not collate this data and therefore are not able to review whether their use of ECT is effective. Perhaps they just assume it is helping. The rates of improvement attributed to ECT during treatment by three of the four Trusts, or at least by their ECT clinicians, 80-90%, 95-100%, and 100%, were, when compared to the literature, incredible.
The 'Clinical Outcomes' section of the latest ECTAS survey reports only CGI scores (Buley et al., 2017) . It reports no data using validated measures or independent observers, and no data beyond the end of treatment.
This pervasive failure to adequately assess the effectiveness of this controversial and intrusive intervention is matched by the failure of the psychiatric research community to do so. There has not been a single study of ECT compared to placebo for over thirty years, despite the fact that none of the 10 that were conducted prior to 1986 found ECT to be any better than placebo beyond the end of treatment, and five found no benefit even during the treatment period (Read & Arnold, 2017; Read & Bentall, 2010; . The continued use of E.C.T., and the huge variation from one locality to another, relies on the genuinely held beliefs of the dwindling number of psychiatrist who use it rather than on any evidence of its effectiveness, for depression, psychosis, or suicide prevention. The psychosocial context within our mental health services that promotes the use of ECT as opposed to psychological treatments, regardless of the research evidence, includes an over reliance on an ideologically driven, simplistic 'medical model', supported by the profession of psychiatry (biological psychiatrists in particular) and the pharmaceutical industry (De Wattignar & Read, 2009; Mosher, Gosden, & Beder, 2013) . This narrow, unbalanced approach is partly maintained, however, by the understandable human need to avoid listening to distressing and depressing experiences and feelings, and to the social causes thereof (Boyle, 2011; Read & Dillon, 2013; Speed, Moncrieff, & Rapley, 2014) .
Adverse effects National Institute of Clinical Excellence (2017) guidelines also state:
Cognitive function should be monitored on an ongoing basis, and at a minimum at the end of each course of treatment.
That 11 of 32 Trusts (34%) could not readily report what measures were in use to assess adverse effects is worrying. The 14 Trusts (44%) that reported using one or more validated scale are clearly taking their ethical responsibilities more seriously. Four Trusts (15%) even referred to assessment of adverse effects beyond the end of treatment and are to be commended for doing so.
That only four Trusts could provide any actual data on adverse effects is particularly worrying. Overall when asked about adverse effects, only two trusts of 56 could provide any data about the best documented long-term side effects of ECT, cognitive dysfunction, and memory loss. The percentage of patients reported to be experiencing cognitive dysfunction by the only two Trusts providing relevant data ranged from 15% to 95%. No Trusts reported any follow-up data on cognitive dysfunction after the end of treatment. These findings suggest that ECT clinicians and their managers are unaware of, or disinterested in, the memory dysfunction that follows almost every ECT treatment, at least temporarily, and which is 'marked and persistent' for at least one in eight (Sackeim et al., 2007) and probably far more (Breggin, 2008; Rose et al., 2003 Rose et al., , 2004 .
Recommendations A return to comprehensive national annual audits seems urgently needed. These should include attention to compliance with N.I.C.E. guidelines and mental health legislation. In the meantime, all mental health service providers must take responsibility for monitoring their own adherence to government guidelines and the law, and should familiarize themselves with the research literature on the long-term benefits and adverse effects of this controversial treatment. A multidisciplinary investigation into the ongoing excessive use of ECT on women and older people seems long overdue.
Limitations
An obvious limitation is that data were received from only 32 Trusts and that responses fell as low as four for data about actual outcomes -positive and negative. These latter response rates, however, constitute important findings in their own right, about whether Trusts are recording and collating the effects (however poorly measured) of such a controversial treatment. Previous surveys of Trusts about ECT, by ECTAS, produced higher response rates (see above), but our lower rate is partly mitigated by gathering data for each of 3 years, spanning 5 years.
The study generated no data from service providers other than NHS Trusts. It seems particularly problematic that some providers are operating beyond the jurisdiction of the FOI Act. This represents an uneven playing field for NHS providers and private organizations in relation to costs and accountability.
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